[go: up one dir, main page]

EP1434579A1 - Derives d'imidazole comme agents anti-inflammatoires - Google Patents

Derives d'imidazole comme agents anti-inflammatoires

Info

Publication number
EP1434579A1
EP1434579A1 EP02769042A EP02769042A EP1434579A1 EP 1434579 A1 EP1434579 A1 EP 1434579A1 EP 02769042 A EP02769042 A EP 02769042A EP 02769042 A EP02769042 A EP 02769042A EP 1434579 A1 EP1434579 A1 EP 1434579A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
group
aryl
combined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02769042A
Other languages
German (de)
English (en)
Other versions
EP1434579B1 (fr
Inventor
Alexander David Frenkel
Sarah Elizabeth Lively
Jay P. Powers
Andrew Smith
Daqing Sun
Craig Tomooka
Zhulun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of EP1434579A1 publication Critical patent/EP1434579A1/fr
Application granted granted Critical
Publication of EP1434579B1 publication Critical patent/EP1434579B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • cytokines appear to play key roles in these processes, particularly IL-1 and TNF. Both cytokines are derived from mononuclear cells and macrophages, along with other cell types. Physiologically, they produce many of the same proinflammatory responses, including fever, sleep and anorexia, mobilization and activation of polymorphonuclear leukocytes, induction of cyclooxygenase and lipoxygenase enzymes, increase in adhesion molecule expression, activation of B-cells, T-cells and natural killer cells, and stimulation of production of other cytokines.
  • cytokines play key roles in a large number of pathological conditions, including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, diabetes, obesity, cancer, sepsis, etc.
  • IL-1 in inflammation has been demonstrated by the ability of the highly specific IL-1 receptor antagonist protein (E -lRa, or IRAP) to relieve inflammatory conditions (for review, see, e.g., Dinarello (1997) Cytokine Growth Factor Rev. 8:253-265).
  • E -lRa highly specific IL-1 receptor antagonist protein
  • IRAP highly specific IL-1 receptor antagonist protein
  • IL-1 treatment of cells induces the formation of a complex consisting of the two IL-1 receptor chains, IL-lRl and IL-lRAcP, and the resulting heterodimer recruits an adaptor molecule designated as MyD88 (Wesche et al. (1999J J. Biol. Chem. 274:19403-19410).
  • TRAF6 can trigger the NIK/IKK kinase cascade to activate the transcription factor NF-kB.
  • NF-kB regulates a number of genes that, in turn, regulate immune and inflammatory responses.
  • IRAKs Four IRAKs have been identified: IRAK-1 (Cao, et al. (1996) Science
  • IRAK-2 Muzio, et al (1997) Science 278:1612-1615
  • the monomyeloic cell-specific IRAK-M also known as IRAK-3 (Wesche, et al. (1999) J. Biol Chem. 274:19403-10) and IRAK-4 (PCT Publication No. WO 01/051641).
  • IRAK proteins have been shown to play a role in transducing signals other than those originating from IL-1 receptors, including signals triggered by activation of IL-18 receptors (Kanakaraj et al. (1999) J. Exp. Med. 189(7): 1129-1138) and LPS receptors (Yang et al. (1999) J.
  • IRAK-2 and IRAK-M have been shown to be capable of reconstituting the response to IL-1 and LPS in an IRAK deficient cell line.
  • the identification of compounds that modulate the function of IRAK proteins represents an attractive approach to the development of therapeutic agents for the treatment of inflammatory, cell proliferative and immune-related conditions and diseases associated with IRAK-mediated signal transduction, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, diabetes, obesity, allergic disease, psoriasis, asthma, graft rejection, cancer and sepsis.
  • the present invention is directed to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase (IRAK) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related and conditions and diseases.
  • IL-1 interleukin-1
  • IRAK receptor-associated kinase
  • the invention is also directed to pharmaceutical compositions comprising these compounds and the use of the subject compounds and compositions in the prevention or treatment of conditions or diseases mediated by IRAK.
  • R 1 is selected from the group consisting of H, (C ⁇ -C 8 )alkyl, hetero(C ⁇ - C 8 )alkyl, fluoro(C ⁇ -C 4 )alkyl, cycloalkyl(C.-C 8 )alkyl, heterocyclo(C 1 -C 8 )alkyl, aryl, aryl(C 1 -C 8 )alkyl, cyclo(C 3 -C 8 )alkyl-(C 1 -C 8 )alkyl, cyclo(C 3 -C 8 )alkylhetero(C 1 -C 8 )alkyl, heterocyclo(C 1 -C 8 )alkyl, arylhetero(Ci-C 8 )alkyl and heteroaryl;
  • R 2 is (C 1 -C 8 )alkyl, hetero(C 1 -C 8 )alkyl, ⁇ erfluoro(C 1 -C 4 )alkyl
  • R 3 and R 4 are independently selected from the group consisting of H, CN, CO 2 R', CONR'R", (C C 4 )alkyl, (C C 4 )heteroalkyl, aryl, heteroaryl, NR'R" and OR';
  • the compounds provided in the above formula are meant to include pharmaceutically acceptable salts and prodrugs thereof.
  • the present invention also provides pharmaceutical compositions comprising a compound of formula I in combination with a pharmaceutically acceptable carrier or excipient.
  • the present invention further provides methods for treating or preventing inflammatory conditions, cell proliferative disorders or immune-related disorders or comprising administering to a subject in need thereof a therapeutically effective amount of one of the foregoing compounds or compositions.
  • the present invention also provides methods for treating or preventing a condition or disorder responsive to IRAK modulation, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I.
  • the present invention also provides methods for treating or preventing a condition or disorder mediated by IRAK comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I.
  • FIG. 1 provides exemplary structures of preferred compounds of the invention.
  • IRAK variants include proteins substantially homologous to native IRAK, i.e., proteins having one or more naturally or non-naturally occurring amino acid deletions, insertions or substitutions (e.g., IRAK derivatives, homologs and fragments).
  • the amino acid sequence of an IRAK variant preferably is at least about 80% identical to a native IRAK, more preferably at least about 90% identical, and most preferably at least about 95% identical.
  • signal transduction refers to a process whereby an extracellular signal (e.g, the concentration of a cytokine, hormone, neurotransmitter, growth factor) is transmitted via a cascade of intracellular protein- protein interactions to the cell nucleus and generates one or more cellular responses (e.g., gene transcription, protein secretion, mitosis, apoptosis).
  • an extracellular signaling molecule e.g, a cytokine, a hormone, a neurotransmitter, a growth factor
  • transmembrane protein receptors can activate one or more signal transduction pathways.
  • treat refers to a method of alleviating or abrogating a disease and/or its attendant symptoms.
  • prevent refers to a method of barring a subject from acquiring a disease.
  • prevent also include reducing a subject's risk of acquiring a disease.
  • the phrase 'TRAK-responsive condition or disorder and related phrases and terms refer to a condition or disorder that responds favorably to modulation of IRAK activity.
  • Favorable responses to IRAK modulation include alleviation or abrogation of the disease and/or its attendant symptoms, inhibition of the disease, i.e., arrest or reduction of the development of the disease, or its clinical symptoms, and regression of the disease or its clinical symptoms.
  • An IRAK-responsive condition or disease may be completely or partially responsive to IRAK-modulation.
  • An IRAK-responsive condition or disorder may be associated with inappropriate, e.g., less than or greater than normal, IRAK-activity. Inappropriate IRAK functional activity might arise as the result of IRAK expression in cells which normally do not express IRAK, decreased IRAK expression (leading to, e.g., lipid and metabolic disorders and diseases) or increased IRAK expression.
  • An IRAK-responsive condition or disease may include an IRAK-mediated condition or disease, defined below.
  • an IRAK-mediated condition or disorder is one in which modulation of IRAK results in some effect on the underlying condition or disorder (e.g., an IRAK inhibitor results in some improvement in patient well-being in at least some patients).
  • NF- ⁇ B-mediated condition or disorder and related phrases and terms refer to a condition or disorder characterized by inappropriate, e.g., less than or greater than normal, NF- ⁇ B activity. Inappropriate NF- KB functional activity might arise as the result of NF- ⁇ B expression in cells which normally do not express NF- ⁇ B, increased NF- ⁇ B expression or degree of intracellular activation (leading to, e.g., inflammatory and autoimmune disorders and diseases) or decreased NF- ⁇ B expression.
  • an NF-kB -mediated condition or disorder may be completely or partially mediated by inappropriate NF- ⁇ B functional activity.
  • an NF- ⁇ B -mediated condition or disorder is one in which modulation of NF- ⁇ B activation results in some effect on the underlying condition or disorder (e.g., an inhibitor of NF- ⁇ B activation results in some improvement in patient well-being in at least some patients).
  • the term "therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • the ability of a compound to inhibit IRAK function can be demonstrated in an enzymatic assay or a cell-based assay (e.g., inhibition of IL-1 -stimulated NF- ⁇ B activation).
  • the "subject” is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human.
  • unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2- (butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3- butynyl, and the higher homologs and isomers.
  • alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
  • dialkylamino refers to an amino group having two attached alkyl groups that can be the same or different.
  • heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quatemized.
  • the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group.
  • the heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule.
  • Up to two heteroatoms may be consecutive, such as, for example, -CH 2 -NH-OCH 3 and - CH 2 -O-Si(CH 3 ) 3 .
  • a prefix such as (C 2 -C 8 ) is used to refer to a heteroalkyl group, the number of carbons (2-8, in this example) is meant to include the heteroatoms as well.
  • a C 2 -heteroalkyl group is meant to include, for example, -CH 2 OH (one carbon atom and one heteroatom replacing a carbon atom) and -CH 2 SH.
  • cycloalkyl and heterocycloalkyl represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively.
  • cycloalkyl and heterocycloalkyl are meant to be included in the terms “alkyl” and “heteroalkyl”, respectively.
  • a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
  • heterocycloalkyl examples include 1-(1,2,5,6- tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3- morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothieh-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
  • cyclo(C 3 -C 8 )alkyl and “(C 3 -C 8 )cycloalkyl” refer to a cyclic hydrocarbon radical having three to eight carbon atoms.
  • a prefix such as (C 3 -C 8 ) is used to refer to a heterocycloalkyl group, e.g., "heterocyclo(C 3 - C 8 )alkyl” or “hetero(C 3 -C 8 )cycloalkyl”
  • the number of carbons (three to eight, in this example) is meant to include the heteroatoms as well.
  • haloalkyl includes monohaloalkyl (alkyl substituted with one halogen atom) and polyhaloalkyl (alkyl substituted with halogen atoms in a number ranging from two to (2m'+l) halogen atoms, where m' is the total number of carbon atoms in the alkyl group).
  • perhaloalkyl means, unless otherwise stated, alkyl substituted with (2m'+l) halogen atoms, where m' is the total number of carbon atoms in the alkyl group.
  • perhalo(C ⁇ -C 4 )alkyl is meant to include trifluoromethyl, pentachloroethyl, l,l,l-trifluoro-2-bromo-2-chloroethyl, and the like.
  • aryl means, unless otherwise stated, a polyunsaturated, typically aromatic, hydrocarbon substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently.
  • heteroaryl refers to aryl groups (or rings) that contain from one to four heteroatoms selected from N, O and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quatemized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2- pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4- oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2- thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3- pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2- benzimidazolyl, 5-indolyl,
  • R', R" and R'" each independently refer to hydrogen, unsubstituted (CrC 8 )alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, alkoxy or thioalkoxy groups, or aryl-(Ci-C 4 )alkyl groups.
  • R' and R" When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
  • -NR'R is meant to include 1-pyrrolidinyl and 4-morpholinyl.
  • alkyl in its broadest sense is meant to include groups such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g., -C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like).
  • haloalkyl e.g., -CF 3 and -CH 2 CF 3
  • acyl e.g., -C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like.
  • the alkyl groups will have from 0-3 substituents, more preferably 0, 1, or 2 substituents, unless otherwise specified.
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CH 2 ) q -U-, wherein T and U are independently -NH-, -O-, -CH 2 - or a single bond, and the subscript q is an integer of from 0 to 2.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r -B-, wherein A and B are independently -CH -, -O-, -NH-, -S-, - S(O)-, -S(O) 2 -, -S(O) 2 NR'- or a single bond, and the subscript r is an integer of from 1 to 3.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • heteroatom is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
  • salts are meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galacturonic acids and the like (see, for example, Berge et al. (1977) J. Phami. Sci. 66:1-19).
  • Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
  • prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
  • An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the "prodrug"), but then is metabolically hydrolyzed to the carboxylic acid, the active entity.
  • Additional examples include peptidyl derivatives of a compound of the invention.
  • Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
  • Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
  • Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.
  • the present invention is directed to compounds, compositions and methods useful in the modulation of IRAK. Accordingly, the compounds of the present invention are compounds which inhibit at least one function or characteristic of a mammalian IRAK polypeptide, for example, a human IRAK polypeptide.
  • IRAK-1 The full-length human IRAK-1 protein (GenBank Accession No. L76191) has been described, see, e.g, Cao et al. (1996) Science 271(5252): 1128-1131, IRAK-1 is an active protein kinase and is capable of autophosphrorylation in vitro. However, it has been shown that the enzymatic activity is not required for an IRAK- mediated cellular response to IL-1, e.g., IL-1 -stimulated NF- ⁇ B activation.
  • IRAK-4 GenBank Accession No. AX196260 is described in PCT Publication No. WO 01/051641.
  • the present invention provides compounds having antiinflammatory and anti-immunoregulatory activity. It is believed that the compounds of the invention will interfere with inappropriate IL-1 induced signal transduction by specifically modulating or inhibiting IRAK function, e.g., IRAK-1 and/or IRAK-4 function.
  • IRAK is an intracellular component of the signaling pathway that is activated by the binding of TL- 1 to the L-1 receptor (IL-IR).
  • IL-IR L-1 receptor
  • IRAK associates with the active receptor complex and transduces the EL-1 signal by interacting with one or more intracellular signaling molecules.
  • Cellular responses to IRAK-mediated signal transduction include increased transcription of genes that regulate inflammatory and immune responses, e.g., NF-kB. Therefore, inhibition of IRAK function, e.g., inhibition of IRAK kinase activity, will inhibit an IRAK-mediated cellular response and treat or prevent an IRAK- mediated condition or disorder.
  • R 1 is H, (C 1 -C 8 )alkyl, hetero(C ⁇ -C 8 )alkyl, fluoro(C ⁇ - G ⁇ alkyl, cycloalkyl(C 1 -C 8 )alkyl, heterocyclo(Ci-C 8 )alkyl, aryl, aryl(C 1 -C 8 )alkyl, arylhetero(C ⁇ -C 8 )alkyl or heteroaryl.
  • R 1 groups are H, ethyl, (3- carboxymethyl)propyl, (2-morpholin-4-yl)ethyl, 1-hydroxyethyl, 1-hydroxypropyl, (carboxyethyl)methyl, 1-hydroxy-n-butyl, (3-hydroxymethyl)phenyl, 2-(2- hydroxymethyl- 1 -propyl)ethyl,
  • R contains one or more asymmetric carbon atoms
  • R includes individual stereoisomers as well as mixtures.
  • R is a, b, c or d and the like, the 1,4-cis and trans isomers and racemates thereof are intended to be within the scope of the invention.
  • R 2 is (Ci-C 8 )alkyl, hetero(C 1 -C 8 )alkyl, perfluoro(C ⁇ -C 4 )alkyl, aryl or heteroaryl.
  • Exemplary R 2 groups are 3-chorophenyl, 3,4-dichlorophenyl, 3- methanesulfonyl, 3-cyanophenyl, 3-carboxymethylphenyl, 4-methoxyphenyl, 3- methylsulfamoylphenyl, 3-biphenyl, (2-fluoro)ethylsulfamoylphenyl, (2- methoxy)ethylsulfamoylphenyl, (2-hydroxy-2-methyl)ethylsulfamoylphenyl, 3- trifluoromethylphenyl, 3-tetrazolylphenyl, 3-triazolylphenyl, 3-nitrophenyl, (3-nitro-4- hydroxymethyl)phenyl, thiophen-2-
  • CR 3 (OR') or CR 3 (NR'R"), wherein the subscript m is an integer from 1 to 2.
  • exemplary Y groups are C(O), SO 2 , C(O)NH and CH 2 .
  • Z 1 and Z 2 are independently H, halogen, CN, CO 2 R ⁇ CONR'R", (d- C 4 )alkyl, (C C 4 )heteroalkyl, perfluoro d-GOalkyl, aryl, heteroaryl, NR'R" or OR'.
  • Z 1 and Z 2 may be combined to form an additional fused 5-, 6-, 7- or 8- membered cycloalkane, heterocycloalkane, aromatic or heteroaromatic ring.
  • Exemplary combinations of Z 1 and Z 2 are Z 1 and Z 2 combined to form an additional fused benzene, cyclohexane, pyridine or tetrahydropyran ring.
  • R 3 and R 4 are independently H, CN, CO 2 R', CONR'R", (C ⁇ -C 4 )alkyl, (C 1 -C 4 )heteroalkyl, aryl, heteroaryl, NR'R" or OR' .
  • R' and R" are independently H, (C ⁇ -C 4 )alkyl, hetero(Ci-C 4 )alkyl, aryl or ary C G alkyl. Alternatively, when R' and R" are attached to nitrogen, R' and R" may be combined with the nitrogen atom to form a 5-, 6- or 7-membered ring.
  • R 3 , R 4 or R' may be combined with R 2 to form a 5-, 6-, 7- or 8-membered ring containing from 0 to 3 heteroatoms selected from the group consisting of O, N, Si and S.
  • compounds of formula I do not include compounds wherein R 1 is 3-(dialkylamino)propyl when Y is C(O) and Z 1 and Z 2 are combined to form an additional fused benzene ring.
  • R 1 is H, unsubstituted (C 1 -C 8 )alkyl, (C]!-C 8 )alkyl substituted with OR', OC(O)R ⁇ CO 2 R ⁇ CONR'R", OC(O)NR'R", NR"C(O)R ⁇ NR"CO 2 R', hydroxy -Ci alkyl or amino(C C 8 )alkyl, hetero(C!-C 8 )alkyl, fluoro(C ⁇ -C 4 )alkyl, cycloalkyl(C ⁇ -C 8 )alkyl, heterocyclo(C ⁇ -C 8 )alkyl, aryl, aryl(Ci-C 8 )alkyl, arylhetero(C ⁇ -C 8 )alkyl or heteroaryl.
  • R 1 is H, (Ci-C 8 )alkyl, (C ⁇ - C 8 )heteroalkyl or aryl.
  • R 1 is substituted (C 1 -C 8 )alkyl.
  • Particularly preferred substituents are OR', NR'R", OC(O)R ⁇ CO 2 R ⁇ CONR'R", OC(O)NR'R", NR"C(O)R' , NR"CO 2 R' , hydroxy(C ⁇ -C 8 )alkyl and amino(C ⁇ -C 8 )alkyl.
  • R 1 is (C 1 -C 8 )alkyl substituted with OH, hydroxy(C ! -C 4 )alkyl or amino(C ⁇ -C 4 )alkyl.
  • R 1 is cyclo(C ⁇ -C 8 )alkyl. In a particularly preferred embodiment, R 1 is cyclohexyl. In another preferred embodiment, R 1 is heterocyclo(C 1 -C 8 )alkyl. In a particularly preferred embodiment, R 1 is tetrahydropyranyl.
  • R 1 is substituted phenyl.
  • Particularly preferred substituents are OR', NR'R", OC(O)R ⁇ CO 2 R ⁇ CONR'R", OC(O)NR'R", NR"C(O)R' , NR"CO 2 R' , hydroxy(C ⁇ -C 8 )alkyl and amino(C ⁇ -C 8 )alkyl.
  • R 1 is phenyl substituted with hydroxy(C 1 -C 4 )alkyl.
  • R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Z and Z are combined to form an additional fused 6-membered cycloalkane or heterocycloalkane, aromatic or heteroaromatic ring.
  • D, E, F and G are independently CR' " or N, each R" ' is independently H, halogen, (Ci-C 4 )alkyl, perfluoro ⁇ rC ⁇ alkyl, (C ⁇ -C 4 )heteroalkyl, aryl, aryl(C ⁇ -C 4 )alkyl, heteroaryl, CN, CO 2 R' , CONR'R", NR'R", NO 2 , OR' , SR' , C(O)R', OC(O)R', N(R")C(O)R', N(R")CO 2 R', N(R " )C(O)NR'R", S(O) m NR'R", S(O) m R or N(R")S(O) m R', and the subscript m is an integer from 1 to 2.
  • R , R , R and R are independently H, halogen, (C ⁇ -C 4 )alkyl, perfluoro(C ⁇ - C 4 )alkyl, (Cj-C 4 )heteroalkyl, aryl, aryl(C ⁇ -C 4 )al yl, heteroaryl, CN, CO 2 R', CONR'R" NR'R", NO 2 , OR', SR', C(O)R', OC(O)R', N(R")C(O)R', N(R")CO 2 R', N(R " )C(O)NR'R", S(O) m NR'R", S(O) m R or N(R")S(O) m R' and the subscript m is an integer from 1 to 2.
  • R 5 , R 6 or R 7 may be combined with an adjacent R group selected from the group consisting of R 5 , R 6 , R 7 and R 8 to form an additional fused 5-, 6-, 7- or 8-membered ring and R 8 may be combined with R 7 to form an additional fused 5-, 6-, 7- or 8-membered ring or R 1 to form an additional 5-, 6-, 7- or 8-membered ring.
  • R 1 , R 2 , R' and R" have the meanings provided above.
  • R and R are.independently H, halogen, (C C 4 )alkyl, CO 2 R ⁇ NR'R", OR', OC(O)R ⁇ N(R")C(O)R' or N(R " )C(O)NR'R".
  • R is H, fluorine, methyl, hydroxymethyl, (dimethylamino)methyl, (methylamino)methyl, amino, carbomethoxy, methoxy,
  • R 7 is H, fluorine, methyl, hydroxymethyl
  • R is H or OH.
  • Another preferred embodiment is represented by the formula (lib):
  • R 5 , R 6 and R 8 are independently H, halogen, (C ⁇ -C 4 )alkyl, perfluoro(C ⁇ - C 4 )alkyl, (Ci-C 4 )heteroalkyl, aryl, ary -GOalkyl, heteroaryl, CN, CO 2 R', CONR'R", NR'R", NO 2 , OR', SR', C(O)R ⁇ OC(O)R', N(R")C(O)R', N(R")CO 2 R', N(R " )C(O)NR'R", S(O) m NR'R", S(O) m R or N(R")S(O) m R', and the subscript m is an integer from 1 to 2.
  • R 6 may be combined with R 5 to form an additional fused 5-, 6-, 7- or 8-membered ring and R 8 may be combined with R 1 to form an additional 5-, 6-, 7- or 8
  • R 5 , R 6 and R 7 are independently H, halogen, ( -C ⁇ alkyl, perfluoro(C ⁇ - C 4 )alkyl, (C x -C 4 )heteroalkyl, aryl, aryl(Ci-C 4 )alkyl, heteroaryl, CN, CO 2 R', CONR'R", NR'R", NO 2 , OR', SR', C(O)R', OC(O)R', N(R")C(O)R', N(R")CO 2 R', N(R " )C(O)NR'R", S(O) m NR'R", S(O) m R or N(R")S(O) m R' and the subscript m is an integer from 1 to 2.
  • R 6 may be combined with R 5 or R 7 to form an additional fused 5-, 6-, 7- or 8-membered ring.
  • J, K, L and M are independently CR a R b , NR a or O and R a and R b are independently H, halogen, CN, CO 2 R', CONR'R", (C ⁇ -C 4 )alkyl, (C C 4 )heteroalkyl, aryl, heteroaryl, NR'R" or OR'. It is to be understood that J, K, L and M are combined to form a stable moiety -J-K-L-M-.
  • Y is C(O), C(O)NR ⁇ S(O) m or CR 3 R 4 .
  • Y is C(O).
  • Y is C(O)NR'.
  • Y is C(O)NH.
  • Y is S(O) m , wherein the subscript m is an integer selected from 1 to 2.
  • Y is SO 2 .
  • Y is CR 3 R 4 .
  • Y is CH 2 .
  • R 2 is phenyl substituted with at least one substituent selected from perfluoro(C 1 -C 4 )alkyl, aryl, heteroaryl, CONR'R", NO 2 , S(O) m NR'R" and S(O) m R .
  • R is phenyl substituted with at least one substituent selected from CF 3 , CF 2 R', phenyl, tetrazolyl, triazolyl, CONHR', NO 2 , SO 2 NHR' and SO 2 R'.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring and Y is C(O), C(O)NR', S(O) m or CR 3 R 4 .
  • Z 1 and Z 2 are combined to form an additional fused benzene ring and Y is C(O), C(O)NR' , S(O) m or CR 3 R 4 .
  • Another group of particularly preferred embodiments is represented by the formula (IV):
  • R 1 , R 2 , R 5 , R 6 , R 7 and R 8 have the meanings and preferred groupings provided above.
  • R 1 , R 2 , R 5 , R 6 , R 7 and R 8 have the meanings and preferred groupings provided above.
  • R , R , R , R and R have the meanings and preferred groupings provided above.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring and R 1 is H, (Ci- C 8 )alkyl, ( -C ⁇ heteroalkyl or aryl. In one particularly preferred embodiment, Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring and R 1 is
  • Z and Z are combined to form an additional fused aromatic or heteroaromatic ring and R 1 is cyclo(C 1 -C 8 )alkyl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring and R 1 is heterocyclo(C 1 -C 8 )alkyl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring and R 1 is phenyl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring and R 1 is substituted phenyl.
  • Z and Z are combined to form an additional fused aromatic or heteroaromatic ring and R 2 is aryl.
  • R 1 is H, (Ci- C 8 )alkyl, (C ⁇ -C 8 )heteroalkyl or aryl and Y is C(O) or C(O)NH.
  • R 1 is substituted (C 1 -C 8 )alkyl and Y is C(O) or C(O)NH.
  • R 1 is cyclo(C 3 -C 8 )alkyl and Y is C(O) or C(O)NH.
  • R 1 is heterocyclo(C 3 -C 8 )alkyl and Y is C(O) or C(O)NH.
  • R 1 is phenyl and Y is C(O) or C(O)NH.
  • R 1 is substituted phenyl and Y is C(O) or C(O)NH.
  • R 1 is H, (Ci-
  • R is substituted (C ⁇ -C 8 )alkyl and R is aryl.
  • R 1 is cyclo(C 3 -C 8 )alkyl and R 2 is aryl.
  • R 1 is heterocyclo(C 3 -C 8 )alkyl and R 2 is aryl.
  • R 1 is phenyl and R 2 is aryl.
  • R 1 is substituted phenyl and R 2 is aryl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • Y is C(O) or C(O)NR' and R 2 is aryl.
  • Still another group of particularly preferred embodiments is represented by the formula (VII):
  • R 9 , R 10 , R 11 , R 12 and R 13 are independently H, halogen, (C ⁇ -C 4 )alkyl, hetero(C 1 -C 4 )alkyl, aryl, aryl(C ⁇ -C 4 )alkyl, heteroaryl, CN, CO 2 R', CONR'R", NR'R", NO 2 , OR', SR', C(O)R ⁇ N(R")C(O)R', N(R")CO 2 R', N(R " )C(O)NR'R", S(O) m NR'R", S(O) m R ' or N(R")S(O) m R' and the subscript m is an integer from 1 to 2.
  • R 9 , R 10 , R 11 , R 12 or R 13 may be combined with an adjacent R group selected from the group consisting of R 9 , R 10 , R 11 , R 12 and R 13 to form an additional fused 5-, 6-, 7- or 8-membered ring.
  • R 1 , R 5 , R 6 , R 7 , R 8 , R' and R" have the meanings and preferred groupings provided above.
  • At least one of R 9 , R 10 , R 11 , R 12 and R 13 is selected from halogen, (C ⁇ -C 4 )alkyl, perfluoro(C 1 -C 4 )alkyl, (Ci- C 4 )heteroalkyl, aryl, aryl(C ⁇ -C )alkyl, heteroaryl, CN, CO 2 R' , CONR'R", NR'R", NO 2 , OR', SR', C(O)R', N(R")C(O)R', N(R")CO 2 R', N(R " )C(O)NR'R", S(O) m NR'R", S(O) m R ' and N(R")S(O) m R'.
  • At least one of R 9 , R 10 , R 11 , R 12 and R 13 is selected from perfluoro ⁇ i-C ⁇ alkyl, aryl, heteroaryl, CONR'R", NO 2 , S(O) m NR'R" and S(O) m R'.
  • at least one of R 9 , R 10 , R 11 , R 12 and R 13 is selected from CF 3 , CF 2 R', phenyl, tetrazolyl, triazolyl, CONHR', NO 2 , SO 2 NHR' and SO 2 R'.
  • R 10 is NO 2 .
  • a further preferred embodiment is represented by the formula (Vile):
  • R 10 is CF 3 .
  • a further preferred embodiment is represented by the formula:
  • R 10 is S(O) m NR'R" or
  • R 10 is
  • Z and Z are combined to form an additional fused aromatic or heteroaromatic ring
  • Y is C(O) or C(O)NR' and R 1 is H, (C C 8 )alkyl, (C ⁇ -C 8 )heteroalkyl or aryl.
  • Z and Z are combined to form an additional fused aromatic or heteroaromatic ring
  • Y is C(O) or C(O)NR' and Rl is substituted (Cl-C8)alkyl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • Y is C(O) or C(O)NR' and Rl is cyclo(Cl-C8)alkyl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • Y is C(O) or C(O)NR' and Rl is heterocyclo(Cl-C8)alkyl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • Y is C(O) or C(O)NR' and Rl is phenyl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring, Y is C(O) or C(O)NR' and Rl is substituted phenyl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • R 1 is H, ( - C 8 )alkyl, (C 1 -C 8 )heteroalkyl or aryl and R is aryl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring, R 1 is substituted (C 1 -C 8 )alkyl and R 2 is aryl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring, R 1 is cyclo(C 3 -C 8 )alkyl and R 2 is aryl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring, R 1 is heterocyclo(C 3 -C 8 )alkyl and R 2 is aryl. In another particularly preferred embodiment, Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring, R 1 is phenyl and R 2 is aryl. In another particularly preferred embodiment, Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring, R 1 is substituted phenyl and R 9 is aryl.
  • Y is C(O) or C(O)NR ⁇ R 1 is H, (C 1 -C 8 )alkyl, (C ⁇ -C 8 )heteroalkyl or aryl and R 2 is aryl.
  • R 1 is substituted ( - C 8 )alkyl and R 2 is aryl.
  • Y is C(O) or C(O)NR ⁇ R 1 is cyclo(C 3 -C 8 )alkyl and R 2 is aryl.
  • Y is C(O) or C(O)NR ⁇ R 1 is heterocyclo(C 3 -C 8 )alkyl and R 2 is aryl.
  • Y is C(O) or C(O)NR' , R 1 is phenyl and R 2 is aryl.
  • Y is C(O) or C(O)NR', R 1 is substituted phenyl and R 2 is aryl.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • R 1 is H, (Ci- C 8 )alkyl, (C ⁇ -C 8 )het ⁇ roalkyl or aryl
  • R 2 is aryl and Y is C(O) or C(O)NR'
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • R 1 is substituted (Cl-C8)alkyl
  • R 2 is aryl and Y is ' C(O) or C(O)NR'.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • Rl is cyclo(Cl- C8)alkyl
  • R 2 is aryl and Y is C(O) or C(O)NR'
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • Rl is heterocyclo(Cl-C8)alkyl
  • R 2 is aryl and Y is C(O) or C(O)NR'.
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring
  • Rl is phenyl
  • R 2 is aryl and Y is C(O) or C(O)NR' .
  • Z 1 and Z 2 are combined to form an additional fused aromatic or heteroaromatic ring, Rl is substituted phenyl, R 2 is aryl and Y is C(O) or C(O)NR'.
  • Another group of particularly preferred embodiments is represented by the formula (Vila):
  • X is H, OR', NR'R", OC(O)R', CO 2 R', CONR'R", OC(O)NR'R", NR"C(O)R' or NR"CO 2 R' and R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 have the meanings and preferred groupings provided above.
  • X is OH.
  • Exemplary compounds of the invention are provided in Figures la-3c.
  • the vast majority of the compounds contemplated for use in the present invention are novel, while some are available from commercial sources.
  • the present invention specifically contemplates the exclusion of commercially available compounds from the compound claims (and, if appropriate, from the pharmaceutical composition claims).
  • the invention includes those compounds that are novel, as well as pharmaceutical compositions, various methods (e.g., methods of treating or preventing certain IRAK- mediated conditions and diseases), and the like which include both the novel compounds of the invention and compounds that are commercially available.
  • Exemplary commercially available benzimidazoles include nocodazole, carbendazim, mebendazole, albendazole, benomyl, thiabendazole, fenbendazole, oxfendazole and flubendazole.
  • the present invention provides pharmaceutical compositions for modulating IRAK.
  • the compositions comprise a compound of the present invention with a pharmaceutically acceptable carrier or excipient.
  • composition as used herein is intended to encompass a product comprising the specified ingredients (and in the specified amounts, if indicated), as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • pharmaceutically acceptable it is meant that the carrier or excipient is compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the invention provides the subject compounds combined with a pharmaceutically acceptable excipient such as sterile saline, methylcellulose solutions, detergent solutions or other medium, water, gelatin, oils, etc.
  • a pharmaceutically acceptable excipient such as sterile saline, methylcellulose solutions, detergent solutions or other medium, water, gelatin, oils, etc.
  • the compounds or compositions may be administered alone or in combination with any convenient carrier, diluent, etc., and such administration may be provided in single or multiple dosages.
  • Useful carriers include water soluble and water insoluble solids, fatty acids, micelles, inverse micelles, liposomes and semi-solid or liquid media, including aqueous solutions and non-toxic organic solvents. All of the above formulations may be treated with ultrasounds, stirred, mixed, high-shear mixed, heated, ground, milled, aerosolized, pulverized, lyophilized, etc. to form pharmaceutically acceptable compositions.
  • compositions for the administration of the compounds of this invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients.
  • the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with other non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in U.S. Patent Nos. 4,256,108; 4,166,452 and 4,265,874 to form osmotic therapeutic tablets for control release.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxy-ethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan mono
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • preservatives for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • flavoring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • sweetening agents such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions. may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile i ⁇ jectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3 -butane diol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • compositions and methods of the present invention may further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment or prevention of the above mentioned pathological conditions.
  • the compounds and compositions of the present invention can be used to treat and/or prevent conditions and disorders associated with IL-1 signaling, such as inflammatory conditions, cancer and various immune disorders.
  • These conditions or disorders include, but are not limited to: (1) inflammatory or allergic diseases such as systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies and food allergies, (2) inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, ileitis and enteritis, (3) vaginitis, (4) psoriasis and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria and pruritus, (5) vasculitis, (6) spondyloarthropathies, (7) scleroderma, (8) asthma and respiratory allergic diseases such as allergic asthma, allergic rhinitis, hypersensitivity lung diseases and the like, (9) autoimmune diseases, such as arthritis (including rheumatoid and
  • the present methods are directed to the treatment of diseases or conditions selected from rheumatoid arthritis, inflammatory bowel disease, allergic disease, psoriasis, asthma, multiple sclerosis, graft rejection and sepsis. More preferably, the present methods are directed to the treatment of rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.
  • the compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICN, intracisternal injection or infusion, subcutaneous injection or implant), inhalation, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
  • the present invention also contemplates administration of the compounds of the present invention in a depot formulation, in which the active ingredient is released over a defined time period.
  • an appropriate dosage level will generally be about 0.001 to 100 mg per kg patient body weight per day which can be administered in single or multiple doses.
  • the dosage level will be about 0.01 to about 25 mg/kg per day; more preferably about 0.05 to about 10 mg/kg per day.
  • a suitable dosage level may be about 0.01 to 25 mg/kg per day, about 0.05 to 10 mg/kg per day, or about 0.1 to 5 mg/kg per day. Within this range the dosage may be 0.005 to 0.05, 0.05 to 0.5 or 0.5 to 5.0 mg/kg per day.
  • the compounds of the present invention can be combined with other compounds having related or complementary utilities to prevent and treat inflammatory and immune-related conditions and diseases, including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and those pathologies noted above.
  • combination therapy is used in the treatment or prevention of a condition or disorder mediated by IRAK.
  • the present compounds may be used in conjunction with an antiinflammatory or analgesic agent such as an opiate agonist, a lipoxygenase inhibitor, such as an inhibitor of 5-lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 (COX-2) inhibitor, an interleukin inhibitor, such as an interleukin-1 receptor antagonist, an NMD A antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine- suppressing antiinflammatory agent, for example with a compound such as acetaminophen, aspirin, codeine, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sulindac, tenidap, and the like.
  • the instant compounds may be administered with an analgesic listed above; a potentiator such as caffeine, an H2-antagonist (e.g., ranitidine), simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxy-ephedrine; an antiitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan; a diuretic; and a sedating or non-sedating antihistamine.
  • a potentiator such as caffeine, an H2-antagonist (e.g., ranitidine), simethicone, aluminum or magnesium hydroxide
  • a decongestant such as phenylephrine, phenylpropan
  • compounds and compositions of the present invention may be used in combination with other drugs that are used in the treatment, prevention, suppression or amelioration of the conditions or diseases for which compounds of the present invention are useful.
  • Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention.
  • a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred.
  • the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients or therapeutic agents, in addition to a compound of the present invention.
  • Examples of other therapeutic agents that may be combined with a compound of the present invention, either administered separately or in the same pharmaceutical compositions include, but are not limited to: (a) NLA-4 antagonists, (b) corticosteroids, such as beclomethasone, methylprednisolone, betamethasone, prednisone, prednisolone, dexamethasone, fluticasone and hydrocortisone, and corticosteroid analogs such as budesonide; (c) immunosuppressants such as cyclosporine (cyclosporine A, Sandimmune®, Neoral®), tacrolimus (FK-506, Prograf®), rapamycin (sirolimus, Rapamune®) and other FK-506 type immunosuppressants, and mycophenolate, e.g., mycophenolate mofetil (CellCept®); (d) antihistamines (Hl-histamine antagonists) such as bromopheniramine, chlorpheni
  • the weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of the compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
  • the present methods are directed to the treatment of rheumatoid arthritis, wherein the compound of the invention is administered either alone or in combination with a second therapeutic agent selected from methotrexate, sulfasalazine, a COX-2 inhibitor, hydroxychloroquine, cyclosporine A, D-penicillamine, infliximab, etanercept , auranofin and aurothioglucose.
  • a second therapeutic agent selected from methotrexate, sulfasalazine, a COX-2 inhibitor, hydroxychloroquine, cyclosporine A, D-penicillamine, infliximab, etanercept , auranofin and aurothioglucose.
  • a second therapeutic agent selected from methotrexate, sulfasalazine, a COX-2 inhibitor, hydroxychloroquine, cyclosporine A, D-penici
  • the present methods are directed to the treatment of inflammatory bowel disease wherein the compound of the invention is used alone or in combination with a second therapeutic agent selected from sulfasalazine and analogs (e.g., olsalazine), mesalamine, corticosteroids (e.g., prednisone, prednisolone) and analogs (e.g., budesonide), azathioprine, 6- mercaptopurine, cyclosporine A, methotrextate, infliximab and an IL-1 inhibitor.
  • a second therapeutic agent selected from sulfasalazine and analogs (e.g., olsalazine), mesalamine, corticosteroids (e.g., prednisone, prednisolone) and analogs (e.g., budesonide), azathioprine, 6- mercaptopurine, cyclosporine A, methotre
  • the present methods are directed to the treatment of multiple sclerosis using a compound of the invention either alone or in combination with a second therapeutic agent selected from interferon ⁇ -l ⁇ , interferon ⁇ -l ⁇ , azathioprine, glatiramer acetate, a glucocorticoid (e.g., prednisolone) and cyclophosphamide.
  • a second therapeutic agent selected from interferon ⁇ -l ⁇ , interferon ⁇ -l ⁇ , azathioprine, glatiramer acetate, a glucocorticoid (e.g., prednisolone) and cyclophosphamide.
  • the present invention includes methods to evaluate putative specific agonists or antagonists of IRAK function. Accordingly, the present invention is directed to the use of these compounds in the preparation and execution of screening assays for compounds which modulate the function of the IRAK.
  • the compounds of this invention are useful for isolating receptor mutants, which are excellent screening tools for potent compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other compounds to IRAK, e.g., by competitive inhibition.
  • the compounds of the instant invention are also useful for the evaluation of putative specific modulators of IRAK.
  • Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA).
  • 1H-NMR spectra were recorded on a Bruker 400 MHz NMR spectrometer. Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad singlet), coupling constant(s) in Hertz (Hz), number of protons.
  • Electron Ionization (El) mass spectra were recorded on a Hewlett Packard 5989A mass spectrometer.
  • Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parentheses). In tables, a single m/e value is reported for the M+H (or, as noted, M-H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all cases.
  • Electrospray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett- Packard 1100 MSD electrospray mass spectrometer using the HP1 100 HPLC for sample delivery.
  • the analyte was dissolved in methanol at 0.1 mg/mL and 1 microliter ( ⁇ L) was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using 1:1 acetonitrile/water with 1% acetic acid as the delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2mM NH OAC in acetonitrile/water as delivery solvent.
  • the flask was then charged with 40 mL DMF, stirring was initiated (magnetic stirrer) and 1.71 mL N- methylmorpholine ( ⁇ MM, 15.48 mmol, 1.15 equiv) was added in one portion to the suspension. After 6 h, the suspension was diluted with 200 mL of a 10% citric acid solution. After stirring an additional 30 min, the suspension was filtered and the resulting solid was washed (2 x H 2 O, then 2 x sat. ⁇ aHCO 3 ). The solid was then triturated with EtOAc (30 mL), filtered, and dried under reduced pressure to give 3.16 g of the product as a tan solid (11.2 mmol).
  • the suspension was then diluted with 10 mL sat. ⁇ a ⁇ CO 3 , and the acetone was removed under reduced pressure.
  • the resulting suspension was then diluted with 20 mL CH 2 C1 2 , shaken until no solids remained, and passed through a 20 mm (40 mL) 3M Empore octadecyl (C18) cartridge to remove water.
  • the collected organics were then concentrated under reduced pressure. Purification by flash chromatography (SiO 2 , 2- 4% MeOH/CH 2 Cl 2 ) gave 124 mg of the product as a tan solid (0.314 mmol).
  • step (e) 3-Nitro-N-(l-(tr ⁇ ns-4-cyclohexanol-l-yl)-5-fluoro-lH- benzoimidazol-2-yl)-benzamide:
  • the ester prepared above in step (d) (100 mg, 0.183 mmol) was combined with MeO ⁇ (10 mL), ⁇ 2 O (3 mL), and THE (3 mL) followed by the addition of 100 mg LiOH.
  • the suspension was heated to 53 °C for 2 h, over which time the suspension slowly went into solution. At the end of 2 h, the solution was concentrated under reduced pressure, diluted with sat. ⁇ aHCO 3 , and extracted 3 x CH 2 C1 2 .
  • the flask was equipped with a reflux condenser, and heated to 150 °C. After stirring for 15 h, the dark red solution was removed from the heating bath and allowed to cool to rt. The reaction was diluted with CH 2 C1 2 (20 mL) and sat. NaHCO 3 (50 mL). The aqueous solution was then extracted (3 x CH C1 2 ), dried (MgSO 4 ), and concentrated under reduced pressure.
  • reaction was diluted with 50 mL sat. NaHCO 3 and 25 mL CH 2 C1 .
  • the aqueous solution was then extracted (3 x CH C1 2 ), and the combined organic layers were dried (MgSO 4 ), filtered, and concentrated under reduced pressure to give the product Nl-phenyl-4-piperidin-l- ylmethyl-benzene-l,2-diamine as a yellow oil which was sufficiently pure to continue to the next step.
  • Steps (a), (b), (c) A solution of 15.1 g of 2-amino-l-phenyl-5- (hydroxymethyl)benzimidazole (63.0 mmol, 1.0 equiv) in 100 mLDMF was added to a 1000 mL flask containing a stirred solution of 56.51 g ⁇ BTU (151 mmol, 2.4 equiv), 20.44 g ⁇ OBT (151 mmol, 2.4 equiv), 28.7 g 3-trifluoromethyl benzoic acid (151 mmol, 2.4 equiv), 210 mL DMF, and 20.8 mL N-methylmorpholine (189 mmol, 3.0 equiv).
  • the solution was allowed to stir for 16 h, at which time 1.5 L 10% aq. citric acid was added.
  • the resulting mixture was stirred for an additional 2 h, then the mixture was filtered, and washed (2 x sat. ⁇ a ⁇ CO 3 , then H 2 O).
  • the mauve product was dissolved in a solution of 800 mL THF, 150 mL MeOH, 50 mL H 2 O, and 7.54 g LiOH (315 mmol, 5.00 equiv).
  • the resulting brown mixture was heated to 50 °C for 1 h, then allowed to cool to rt, at which time the reaction mixture was diluted with 300 mL sat. NaHCO 3 and 100 mL EtOAc.
  • the benzoic acid was prepared as follows: To a solution of 2- fluoroethylamide (945 mg, 15 mmol) in dichloromethane (20 mL) was added 3- chlorosulfonylbenzoic acid (1.20 g, 5.44 mmol). After stirring at room temperature for 16 hr, the reaction mixture was diluted with ethyl acetate (50 mL) and extracted with sodium hydroxide (2 x 50 mL, IN, aq.). The combined aqueous extracts were acidified to pH 5. The mixture was then filtered to afford (2-fluoroethylsulfamoyl)benzoic acid (640 mg) as a white powder which was used in the synthesis of the title compound without further purification.
  • Enzymatic inhibition assay This example provides a method that is useful for evaluating test compounds for inhibition of IRAK-1 or IRAK-4 kinase activity.
  • IRAK-1 or streptavidin for IRAK-4 (10 mg/mL in PBS, overnight at 4 °C).
  • the coating solution was removed and in 80 ⁇ L/well a kinase reaction mixture was added (for IRAK-1: 20 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 , 2 mM EGTA, 1 mM NaF, 0.5 mM benzamidine, 1 mM DTT, 3 ⁇ M ATP, lmM of biotinylated substrate peptide bio- ARFSRFAGSSPSQSSMNAR, sequence derived from IRAK-1; for IRAK-4: 20 mM Tris-HCI, pH 7.5, 10 mM MgCl 2 , 2 mM EGTA, 1 mM ⁇ aF, 0.5 mM benzamidine, 1 mM DTT, 10% glycerol, 10 ⁇ M ATP, lmM of biotinyl
  • test compounds were added covering a final concentration range from InM to 30mM.
  • Recombinant, full-length IRAK-1 or IRAK-4 enzyme (baculovirus expression system) was added in 10 ⁇ L buffer containing Tris- HCI pH 7.5 20 mM, EGTA 2 mM, benzamidine 0.5 mM, DTT 1 mM, MgCl 2 10 mM and glycerol 10% (IRAK-4 only) to initiate the kinase reaction.
  • the reaction mixture was incubated at room temperature for 60 min on a shaker.
  • a conventional chemiluminescent ELISA detection technique was initiated by adding 100 ⁇ L/well primary antibody (monoclonal antibody YC10, generated to recognize the phosphorylated epitope in the substrate peptide; used at 1:20,000 dilution for IRAK-1 and 1:10,000 dilution for IRAK-4) premixed with horseradish peroxidase (HRP) conjugated anti-mouse secondary antibody (commercially available from several sources; used at 1 : 10,000 dilution) in PBS containing 2% BSA. The solution was incubated at room temperature for 40 min on a shaker, then washed 3x with 150 ⁇ L of water.
  • primary antibody monoclonal antibody YC10, generated to recognize the phosphorylated epitope in the substrate peptide; used at 1:20,000 dilution for IRAK-1 and 1:10,000 dilution for IRAK-4
  • HRP horseradish peroxidase conjugated anti-mouse secondary antibody

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés (I) et des compositions pharmaceutiques contenant ceux-ci, utiles dans le traitement d'affections ou de troubles inflammatoires et associés au système immunitaire. Elle concerne en particulier des composés qui modulent l'expression et/ou la fonction de protéines intervenant dans l'inflammation, la régulation des réactions immunitaires et la prolifération cellulaire. Toutes les définitions sont décrites dans la demande.
EP02769042A 2001-10-09 2002-10-09 Derives d'imidazole comme agents anti-inflammatoires Expired - Lifetime EP1434579B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32781801P 2001-10-09 2001-10-09
US327818P 2001-10-09
PCT/US2002/032437 WO2003030902A1 (fr) 2001-10-09 2002-10-09 Derives d'imidazole comme agents anti-inflammatoires

Publications (2)

Publication Number Publication Date
EP1434579A1 true EP1434579A1 (fr) 2004-07-07
EP1434579B1 EP1434579B1 (fr) 2011-06-08

Family

ID=23278199

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02769042A Expired - Lifetime EP1434579B1 (fr) 2001-10-09 2002-10-09 Derives d'imidazole comme agents anti-inflammatoires

Country Status (8)

Country Link
US (3) US7132438B2 (fr)
EP (1) EP1434579B1 (fr)
JP (1) JP4445262B2 (fr)
AT (1) ATE511840T1 (fr)
AU (1) AU2002332099B2 (fr)
CA (1) CA2458533C (fr)
ES (1) ES2367422T3 (fr)
WO (1) WO2003030902A1 (fr)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214019A (pt) 2001-11-09 2004-10-13 Boehringer Ingelheim Phamaceut Benzimidazóis úteis como inibidores de proteìna quinase
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
CA2488801A1 (fr) 2002-06-07 2003-12-18 3M Innovative Properties Company Imidazopyridines a substitution ether
US7138420B2 (en) * 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
EP1567507B1 (fr) 2002-11-27 2006-06-14 Boehringer Ingelheim Pharmaceuticals Inc. Inhibiteurs de cytokines a base de derives de 1, 2, 3- triazole-amides
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005000795A2 (fr) * 2003-06-10 2005-01-06 Smithkline Beecham Corporation Composes chimiques
ATE538787T1 (de) * 2003-07-11 2012-01-15 Merck Patent Gmbh Benzimidazol-derivative als raf-kinase-hemmer
CA2531856C (fr) * 2003-07-11 2013-07-30 Merck Patent Gesellschaft Mit Beschraenkter Haftung Benzimidazole carboxamides utilises en tant qu'inhibiteurs de la kinase raf
AU2004266641A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
WO2005018555A2 (fr) * 2003-08-14 2005-03-03 3M Innovative Properties Company Modificateurs de la reponse immunitaire a modification lipidique
EP1658076B1 (fr) 2003-08-27 2013-03-06 3M Innovative Properties Company Imidazoquinolines substituees par aryloxy et arylalkyleneoxy
US20050054665A1 (en) 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
JP2007511535A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
US7897767B2 (en) * 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
CA2547085A1 (fr) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine, et imidazoquinoleines, et imidazopyridines et imidazonaphtyridine substitues d'oxime
US7511042B2 (en) 2003-12-03 2009-03-31 Boehringer Ingelheim Pharmaceuticals, Inc. Triazole compounds
CA2549216A1 (fr) * 2003-12-04 2005-08-25 3M Innovative Properties Company Ethers cycliques imidazo substitues au sulfone
WO2005066170A1 (fr) 2003-12-29 2005-07-21 3M Innovative Properties Company Imidazoquinolines a substitution arylalcenyle et arylalkynyle
EP1699792A1 (fr) * 2003-12-29 2006-09-13 3M Innovative Properties Company Composes de cycles accoles imidazo de piperazine, 1,4¨diazepane, 1,4¨diazocane, et 1,5¨diazocane
CA2551399A1 (fr) 2003-12-30 2005-07-21 3M Innovative Properties Company Sulfonamides d'imidazoquinolinyle, d'imidazopyridinyle et d'imidazonaphtyridinyle
US20050176792A1 (en) * 2004-01-14 2005-08-11 Boehringer Ingelheim Pharmaceuticals, Inc. Ketone substituted benzimidazole compounds
US20050209284A1 (en) * 2004-02-12 2005-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors
CN1930144A (zh) 2004-03-09 2007-03-14 贝林格尔·英格海姆药物公司 可用作细胞因子产生抑制剂用于治疗慢性炎性疾病的3,4’－杂环基－1,2,3－三唑－1－基－n－芳基苯甲酰胺
EP1730143A2 (fr) 2004-03-24 2006-12-13 3M Innovative Properties Company Imidazopyridines, imidazoquinolines, et imidazonaphthyridines a substitution amide
PL366690A1 (en) * 2004-03-29 2005-10-03 Fundacja Rozwoju Diagnostyki I Terapii New derivatives of 4,5,6,7-tetrabromobenzimidazole and method for their obtaining
WO2005108387A2 (fr) 2004-05-03 2005-11-17 Boehringer Ingelheim Pharmaceuticals, Inc. Inhibiteurs de cytokines
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
WO2005123079A2 (fr) * 2004-06-14 2005-12-29 3M Innovative Properties Company Imidazopyridines, imidazoquinolines et imidazonaphthyridines a substitution uree
WO2005123080A2 (fr) 2004-06-15 2005-12-29 3M Innovative Properties Company Imidazoquinolines et imidazonaphthyridines substituees par un heterocyclyle contenant un azote
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006065280A2 (fr) 2004-06-18 2006-06-22 3M Innovative Properties Company Composes a noyau imidazo a substitutif d'isoxazole, de dihydroisoxazole et d'oxadiazole
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (fr) 2004-06-18 2006-04-13 3M Innovative Properties Company Imidazonaphthyridines substituees par aryle
WO2006009826A1 (fr) 2004-06-18 2006-01-26 3M Innovative Properties Company Thiazoloquinolines et thiazolonaphtyridines substitues par aryloxy et arylalkyleneoxy
PL1789042T3 (pl) * 2004-09-02 2012-09-28 3M Innovative Properties Co Układy pierścieni 1-alkoksy 1H-imidazo i sposoby
CA2578975A1 (fr) 2004-09-02 2006-03-16 3M Innovative Properties Company Systemes cycliques de 2-amino 1h imidazo et procedes correspondants
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
NZ556399A (en) * 2004-12-30 2009-03-31 Takeda Pharmaceutical 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine methanesulfonate
CA2592904C (fr) 2004-12-30 2015-04-07 3M Innovative Properties Company Composes chiraux a cycle [1,2]imidazo[4,5] fusionne
US8461174B2 (en) * 2004-12-30 2013-06-11 3M Innovative Properties Company Treatment for cutaneous metastases
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2006086449A2 (fr) 2005-02-09 2006-08-17 Coley Pharmaceutical Group, Inc. Thiazoloquinolines et thiazolonaphthyridines a substitution alcoxy
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
WO2006091394A2 (fr) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Imidazoquinolines et imidazonaphthyridines substituees
WO2006086634A2 (fr) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Composes cycliques imidazo[4,5-c] substitues par oxime et hydroxylamine et procedes associes
EP1851218A2 (fr) 2005-02-23 2007-11-07 3M Innovative Properties Company Composes d'imidazoquinolines a substitution hydroxyalkyle et procedes
EP1851220A2 (fr) 2005-02-23 2007-11-07 3M Innovative Properties Company Imidazonaphthyridines a substitution hydroxyalkyle
JP2008538203A (ja) 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
WO2006098852A2 (fr) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Imidazoquinolines a substitution hydroxyalkyle
US7893267B2 (en) * 2005-03-14 2011-02-22 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
JP2008539252A (ja) * 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー 免疫活性化組成物
AU2006277684A1 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual NOS inhibitory activity and muopioid agonist activity
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
EA200800782A1 (ru) 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007056112A2 (fr) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. 1h-imidazoquinolines substituees par hydroxy et alcoxy et procedes correspondants
EP1800673A3 (fr) * 2005-12-23 2007-08-15 Canadian Blood Services Nitrophényles et composés associés et thimérosal pour l'inhibition de la destruction cellulaire ou tissulaire liée à l'immunité
WO2007100634A2 (fr) 2006-02-22 2007-09-07 3M Innovative Properties Company Conjugués du modificateur de réponse immune
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
GB0606429D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Organic compounds
WO2007113202A1 (fr) 2006-03-31 2007-10-11 Glaxo Group Limited Dérivés de pipérazine utilisés comme agonistes du récepteur du sécrétagogue de l'hormone de croissance (shc)
US20110071130A1 (en) * 2006-05-08 2011-03-24 Pharmacopeia, Inc. 2-aminobenzimidazoles for treating neurodegenerative diseases
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2008030511A2 (fr) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. 3, 4, 6, 7-tétrahydro-5h-1, 2a, 4a, 8-tétraazacyclopenta[cd]phénalènes substitués
EP2061786A2 (fr) 2006-09-07 2009-05-27 Biogen Idec MA Inc. Modulateurs de la kinase associée au récepteur de l'interleukine-1
WO2008036747A2 (fr) * 2006-09-21 2008-03-27 Amarillo Biosciences, Inc. Composition et procédé d'immunomodulation
US7790635B2 (en) * 2006-12-14 2010-09-07 Applied Materials, Inc. Method to increase the compressive stress of PECVD dielectric films
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
ES2554513T3 (es) 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
EP2243481A1 (fr) 2009-04-24 2010-10-27 PamGene B.V. Famille de kinase Irak en tant que nouvelle cible de médicament pour Alzheimer
DE102009033208A1 (de) 2009-07-15 2011-01-20 Merck Patent Gmbh Aminopyridinderivate
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
CN102712601A (zh) 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
KR101995013B1 (ko) 2010-07-13 2019-07-02 에프. 호프만-라 로슈 아게 Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
CN103168032A (zh) * 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
HRP20170433T1 (hr) 2010-08-17 2017-05-05 3M Innovative Properties Company Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
PE20140192A1 (es) 2010-10-06 2014-02-24 Glaxosmithkline Llc Derivados de bencimidazol como inhibidores de cinasa pi3
EP2688872A4 (fr) 2011-03-22 2014-08-27 Merck Sharp & Dohme Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole
CN103582496B (zh) 2011-06-03 2016-05-11 3M创新有限公司 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
WO2012167081A1 (fr) 2011-06-03 2012-12-06 3M Innovative Properties Company Hydrazino 1h-imidazoquinoléine-4-amines et conjugués obtenus à partir de celles-ci
US9464326B2 (en) * 2012-03-22 2016-10-11 University Of Maryland, Baltimore Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
IN2014MN02562A (fr) 2012-06-27 2015-07-24 4Sc Discovery Gmbh
EP2890691B1 (fr) 2012-08-31 2018-04-25 Principia Biopharma Inc. Dérivés de benzimidazole en tant qu'inhibiteurs d'itk
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
CN103012239B (zh) * 2013-01-11 2015-07-01 华东理工大学 一种2-硝基-4-(1h-吡咯甲基)-n-取代苯胺衍生物的制备方法
RS56269B1 (sr) * 2013-02-07 2017-11-30 Merck Patent Gmbh Makrociklični piridazinon derivati
US9567320B2 (en) * 2013-02-07 2017-02-14 Merck Patent Gmbh Pyridazinone-amides derivatives
EP2970194A1 (fr) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Sels et formes solides d'isoquinolinones et compositions les comprenant et procédés pour les utiliser
WO2014190163A2 (fr) * 2013-05-22 2014-11-27 Children's Hospital Medical Center Polythérapie pour mds
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20160166576A1 (en) 2013-07-11 2016-06-16 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10005765B2 (en) 2014-03-20 2018-06-26 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CA2952069C (fr) 2014-06-16 2022-06-14 University Of Rochester Agents anti-cicatrices formes de petites molecules
BR112017001918A2 (pt) * 2014-07-31 2017-11-28 Pasteur Institut Korea derivados de 2-amino-benzimidazol e seu uso como inibidores de 5-lipoxigenase e/ou prostaglandina e sintase
EP3715346B1 (fr) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Composés contenant des groupes thiazolyle pour le traitement de maladies prolifératives
AU2016323613B2 (en) * 2015-09-18 2020-12-10 Merck Patent Gmbh Heteroaryl compounds as IRAK inhibitors and uses thereof
RU2743716C2 (ru) * 2015-09-18 2021-02-24 Мерк Патент Гмбх Гетероарильные соединения в качестве ингибиторов irak и их применение
WO2017207340A1 (fr) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Nouveaux benzimidazoles substitués, leur procédé de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la production de médicaments
US11254667B2 (en) 2016-08-17 2022-02-22 Children's Hospital Medical Center Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
US11542261B2 (en) 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HRP20250396T1 (hr) 2016-08-31 2025-05-23 Mapi Pharma Ltd. Depo sustavi koji sadrže glatiramer acetat
WO2018060072A1 (fr) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Nouveaux benzimidazoles substitués, leur procédé de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la production de médicaments
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
WO2018060174A1 (fr) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Benzimidazoles substitués, préparations pharmaceutiques les contenant et leur utilisation pour la production de médicaments
WO2018081361A1 (fr) 2016-10-28 2018-05-03 Children's Hospital Medical Center Procédés et compositions pour le traitement de syndromes myélodyspastiques et/ou de leucémies aiguës myléoïdes
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
EP3728255B1 (fr) 2017-12-20 2022-01-26 3M Innovative Properties Company Composés imidazo [4,5-c]quinoléine à substitution amide ayant un groupe de liaison à chaîne ramifiée destinés à être utilisés en tant que modificateur de la réponse immunitaire
JP2021512166A (ja) 2018-01-30 2021-05-13 フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 化合物及びその使用
US11174245B2 (en) 2018-02-21 2021-11-16 Boehringer Ingelheim International Gmbh Benzimidazole compounds and derivatives as EGFR inhibitors
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US20220380382A1 (en) 2019-06-24 2022-12-01 Boehringer Ingelheim International Gmbh New macrocyclic compounds and derivatives as egfr inhibitors
JP7386576B2 (ja) * 2019-10-02 2023-11-27 カイノス・メディスン・インコーポレイテッド Ｎ－（１ｈ－イミダゾール－２－イル）ベンズアミド化合物および該化合物を活性成分として含む医薬組成物
US20230121497A1 (en) * 2020-01-29 2023-04-20 Foghorn Therapeutics Inc. Compounds and uses thereof
JP7561195B2 (ja) 2020-01-29 2024-10-03 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
WO2022076589A1 (fr) * 2020-10-07 2022-04-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs covalents d'egfr et leurs procédés d'utilisation
WO2022081478A1 (fr) * 2020-10-12 2022-04-21 Dana-Farber Cancer Institute, Inc. Inhibiteurs covalents du r-egf et leurs méthodes d'utilisation
EP4323356A1 (fr) 2021-04-13 2024-02-21 Nuvalent, Inc. Hétérocycles amino-substitués pour le traitement de cancers avec des mutations egfr
CN115109011B (zh) * 2022-08-10 2023-12-15 河北师范大学 一种苯并噻唑类化合物、制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE241684C (fr) *
US2928833A (en) * 1959-03-03 1960-03-15 S E Massengill Company Theophylline derivatives
US4011236A (en) * 1968-09-09 1977-03-08 Merck & Co., Inc. N-(benzimidazol-2-yl)arylcarboxamides as ultraviolet (uv) light absorbers
NL6913261A (fr) 1968-09-09 1970-03-11
US3880874A (en) 1973-10-04 1975-04-29 Syntex Inc 2-Substituted -1,2,4-thiadiazolo-(2,3-a)benzimidazoles and process for their preparation
FR2269341B1 (fr) * 1974-04-30 1978-07-28 Castaigne Sa
US4002623A (en) * 1974-08-07 1977-01-11 Pfizer Inc. Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)-propyl]imidazo[4,5-b]pyridines
US4088768A (en) * 1975-05-06 1978-05-09 Eli Lilly And Company N-heterocyclic ureas as immune regulants
FR2384757A1 (fr) 1977-03-25 1978-10-20 Parcor Composes sulfonylamines
US4492708A (en) * 1982-09-27 1985-01-08 Eli Lilly And Company Antiviral benzimidazoles
US5654397A (en) 1985-06-23 1997-08-05 Tularik, Inc. Interleukin-1 receptor-associated protein kinase and assays
US4835161A (en) * 1986-02-03 1989-05-30 Janssen Pharmaceutica N.V. Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines
JPS63159861A (ja) 1986-12-24 1988-07-02 Canon Inc 電子写真感光体
US4874864A (en) 1988-05-24 1989-10-17 Pfizer Inc. Benzamide protease inhibitors
JPH0772181B2 (ja) 1989-06-26 1995-08-02 株式会社大塚製薬工場 ベンズイミダゾール誘導体
US5362591A (en) * 1989-10-09 1994-11-08 Hitachi Ltd. Et Al. Mask having a phase shifter and method of manufacturing same
DE69327572T2 (de) 1992-05-21 2000-06-21 Otsuka Pharmaceutical Factory, Inc. Phosphonsäurediester-derivat
TW260664B (fr) 1993-02-15 1995-10-21 Otsuka Pharma Factory Inc
WO1994022846A1 (fr) * 1993-03-30 1994-10-13 Pfizer Inc. Composes stimulant l'activite antitumorale d'autres agents cytotoxiques
US5683999A (en) 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
GB9600142D0 (en) 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
CA2308428A1 (fr) * 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Composes heterocycliques aromatiques convenant comme anti-inflammatoires
JPH11302177A (ja) 1998-04-27 1999-11-02 Otsuka Pharmaceut Factory Inc 腎炎治療剤
ATE292120T1 (de) 1998-07-02 2005-04-15 Neurosearch As Kaliumkanal-blockierende mittel
ES2237966T3 (es) 1998-08-20 2005-08-01 Agouron Pharmaceuticals, Inc. Agentes de gnrh no peptidicos, metodos y compuestos intermedios para su preparacion.
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6511983B1 (en) 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
GB9913180D0 (en) 1999-06-08 1999-08-04 Glaxo Group Ltd Interleukin-1 receptor associated kinases
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
JP2001199968A (ja) 2000-01-18 2001-07-24 Teijin Ltd アミノベンズイミダゾール誘導体
AU2001219185A1 (en) * 2000-03-17 2001-10-03 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03030902A1 *

Also Published As

Publication number Publication date
ATE511840T1 (de) 2011-06-15
CA2458533C (fr) 2011-01-04
AU2002332099B8 (en) 2003-04-22
US7132438B2 (en) 2006-11-07
US20100048565A1 (en) 2010-02-25
ES2367422T3 (es) 2011-11-03
US7635774B2 (en) 2009-12-22
EP1434579B1 (fr) 2011-06-08
US20030144286A1 (en) 2003-07-31
JP4445262B2 (ja) 2010-04-07
JP2005532251A (ja) 2005-10-27
US20070037803A1 (en) 2007-02-15
CA2458533A1 (fr) 2003-04-17
WO2003030902A1 (fr) 2003-04-17
AU2002332099B2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
EP1434579B1 (fr) Derives d'imidazole comme agents anti-inflammatoires
AU2002332099A1 (en) Imidazole derivates as antiinflammatory agents
US6794379B2 (en) CXCR3 antagonists
EP1300398B1 (fr) Derives de propane-1,3-dione
AU2001297717B2 (en) CXCR3 antagonists
CN100357278C (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
EP2780338B1 (fr) Dérivés d'uracile comme inhibiteurs d'axl et c-met kinases
KR102450671B1 (ko) 리신 특이적 데메틸라제-1의 저해제
US20030018022A1 (en) Ccr4 antagonists
JP2019108346A (ja) リジン特異的なデメチラーゼ−１の阻害剤
JP2009531364A (ja) アミド誘導体およびｇタンパク質関連疾患の処置のためのそれらの使用
ZA200500790B (en) Substituted quinoline CCR5 receptor antagonists
PT2305250E (pt) Derivados de benzimidazol e seu uso como inibidores de proteínas quinases
US20030181472A1 (en) Inflammation modulators
KR20150037877A (ko) 암, 자가면역성 염증 및 중추신경계 장애를 치료하기 위한 비플루오로디옥살란-아미노-벤즈이미다졸 키나제 억제제
US20080004325A1 (en) PTP1B inhibitors
JP2005511760A (ja) 新規な化合物
JP2002145778A (ja) Ｇｒｋ阻害剤
WO2006038989A1 (fr) Arylamides substitues
WO2006088813A1 (fr) Pyrazoles substitues comme modulateurs des recepteurs des chimiokines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040311

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20060503

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMGEN INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAC Information related to communication of intention to grant a patent modified

Free format text: ORIGINAL CODE: EPIDOSCIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: RENTSCH PARTNER AG

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60240242

Country of ref document: DE

Effective date: 20110721

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2367422

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20111103

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20110608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111010

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20120309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60240242

Country of ref document: DE

Effective date: 20120309

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111009

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20120630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110608

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20130911

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20131009

Year of fee payment: 12

Ref country code: CH

Payment date: 20131014

Year of fee payment: 12

Ref country code: DE

Payment date: 20131002

Year of fee payment: 12

Ref country code: GB

Payment date: 20131009

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20131016

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60240242

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20141009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150501

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141031

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141009

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141031

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141009

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141031

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141010